Seres reports additional Phase Ib data for SER-287 in UC

Seres Therapeutics Inc. (NASDAQ:MCRB) presented additional data from a Phase Ib trial to treat ulcerative colitis (UC) showing that one of three regimens of SER-287 significantly improved the secondary endpoint of clinical remission rate as measured by total modified Mayo score. Specifically, once-daily SER-287 with vancomycin pretreatment

Read the full 475 word article

User Sign In